|
|
|
|
Bridge the gap between in vitro research and human physiology by utilizing high-purity primary cells. Accessing diverse cell types and optimized media ensures your gene therapy discovery remains biologically relevant and reproducible.
|
|
|
|
|
In this two-minute preview, we take a high-level look at the entire gene therapy development journey — from discovery and preclinical research to process development, manufacturing, regulatory engagement, and clinical trials. Along the way, we highlight the critical bottlenecks that often stand between promising science and successful patient delivery.
|
|
|
|
|
Recent data shows that using a chemically defined, animal-origin-free media system can significantly improve AAV production across serotypes such as AAV2, AAV8, and AAV9. Optimizing viral titer and full capsid yield requires systematic process development, with cell culture medium selection serving as a foundational factor.
|
|
|
|
|
|
|
